Kingdon Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Kingdon Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$3.78M	–	98
2022 Q1	$3.78M	Buy	100,000 +48,668	+95%	+$1.92M	0.39%	55
2021 Q4	$2.03M	Buy	+51,332	New	+$1.61M	0.23%	66
2021 Q3	–	Sell	-8,317	Closed	-$204K	–	85
2021 Q2	$204K	Sell	8,317 -31,683	-79%	-$707K	0.02%	66
2021 Q1	$730K	Buy	+40,000	New	+$826K	0.07%	61

Other funds holding RXDX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kingdon Capital Management's RXDX Position: Q2 2022 in Review

Kingdon Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2022, closing a stake of 100,000 shares — an estimated $3.78M sold.

Kingdon Capital Management first reported a position in RXDX in Q1 2021 and held it in 4 quarters. The position peaked at $3.78M in Q1 2022. 116 funds tracked by Wall St. Rank hold RXDX as of Q2 2022.

Kingdon Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Kingdon Capital Management sold 100,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $3.78M.
Kingdon Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Kingdon Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $3.78M in Q1 2022.
116 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2022.

Based on Kingdon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.